BACKGROUND: MicroRNAs (miRNAs) are noncoding RNA molecules that play important roles in the pathogenesis of various kidney diseases. We investigated whether patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) have distinct circulating and urinary miRNA expression profiles that could lead to potential development of noninvasive biomarkers of the disease. MATERIALS AND METHODS: Exosome miRNAs were extracted from plasma and urine samples of patients with primary FSGS (n = 16) or MCD (n = 5) and healthy controls (n = 5). Differences in miRNA abundance were examined using Affymetrix GeneChip miRNA 3.0 arrays. QRT-PCR was used to validate the findings from the array. RESULTS: Comparison analysis of FSGS versus MCD revealed 126 and 155 differentially expressed miRNAs in plasma and in urine, respectively. Only 38 of these miRNAs were previously cited, whereas the remaining miRNAs have not been described. Comparison analysis showed that a significant number of miRNAs were downregulated in both plasma and urine samples of patients with FSGS compared to those with MCD. Plasma levels of miR-30b, miR-30c, miR-34b, miR-34c and miR-342 and urine levels of mir-1225-5p were upregulated in patients with MCD compared to patients with FSGS and controls (P < 0.001). Urinary levels of mir-1915 and miR-663 were downregulated in patients with FSGS compared to MCD and controls (P < 0.001), whereas the urinary levels of miR-155 were upregulated in patients with FSGS when compared to patients with MCD and controls (P < 0.005). CONCLUSIONS: Patients with FSGS and MCD have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and MCD warrants further studies.
BACKGROUND: MicroRNAs (miRNAs) are noncoding RNA molecules that play important roles in the pathogenesis of various kidney diseases. We investigated whether patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) have distinct circulating and urinary miRNA expression profiles that could lead to potential development of noninvasive biomarkers of the disease. MATERIALS AND METHODS: Exosome miRNAs were extracted from plasma and urine samples of patients with primary FSGS (n = 16) or MCD (n = 5) and healthy controls (n = 5). Differences in miRNA abundance were examined using Affymetrix GeneChip miRNA 3.0 arrays. QRT-PCR was used to validate the findings from the array. RESULTS: Comparison analysis of FSGS versus MCD revealed 126 and 155 differentially expressed miRNAs in plasma and in urine, respectively. Only 38 of these miRNAs were previously cited, whereas the remaining miRNAs have not been described. Comparison analysis showed that a significant number of miRNAs were downregulated in both plasma and urine samples of patients with FSGS compared to those with MCD. Plasma levels of miR-30b, miR-30c, miR-34b, miR-34c and miR-342 and urine levels of mir-1225-5p were upregulated in patients with MCD compared to patients with FSGS and controls (P < 0.001). Urinary levels of mir-1915 and miR-663 were downregulated in patients with FSGS compared to MCD and controls (P < 0.001), whereas the urinary levels of miR-155 were upregulated in patients with FSGS when compared to patients with MCD and controls (P < 0.005). CONCLUSIONS:Patients with FSGS and MCD have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and MCD warrants further studies.
Authors: Jaakko Patrakka; Vesa Ruotsalainen; Ilkka Ketola; Christer Holmberg; Markku Heikinheimo; Karl Tryggvason; Hannu Jalanko Journal: J Am Soc Nephrol Date: 2001-02 Impact factor: 10.121
Authors: Johan M Lorenzen; Jan T Kielstein; Carsten Hafer; Shashi K Gupta; Philipp Kümpers; Robert Faulhaber-Walter; Hermann Haller; Danilo Fliser; Thomas Thum Journal: Clin J Am Soc Nephrol Date: 2011-06-23 Impact factor: 8.237
Authors: Mariana Cardenas-Gonzalez; Anand Srivastava; Mira Pavkovic; Vanesa Bijol; Helmut G Rennke; Isaac E Stillman; Xiaolan Zhang; Samir Parikh; Brad H Rovin; Maryam Afkarian; Ian H de Boer; Jonathan Himmelfarb; Sushrut S Waikar; Vishal S Vaidya Journal: Clin Chem Date: 2017-06-30 Impact factor: 8.327
Authors: Maria Angeles Baker; Seth J Davis; Pengyuan Liu; Xiaoqing Pan; Anna Marie Williams; Kenneth A Iczkowski; Sean T Gallagher; Kaylee Bishop; Kevin R Regner; Yong Liu; Mingyu Liang Journal: J Am Soc Nephrol Date: 2017-06-29 Impact factor: 10.121
Authors: Soon Hyo Kwon; Hui Tang; Ahmed Saad; John R Woollard; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Am J Kidney Dis Date: 2016-03-16 Impact factor: 8.860
Authors: Denis Delić; Claudia Eisele; Ramona Schmid; Patrick Baum; Franziska Wiech; Martin Gerl; Heike Zimdahl; Steven S Pullen; Richard Urquhart Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240